MARKET

PRNAF

PRNAF

Alterity Therapeutics Ltd
OTCPK
0.350
NaN%
Opening 09:30 08/21 EDT
OPEN
--
PREV CLOSE
0.350
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.540
52 WEEK LOW
0.010
MARKET CAP
76.42M
P/E (TTM)
-6.7829
1D
5D
1M
3M
1Y
5Y
1D
Alterity Therapeutics seeks ASX quotation for new ordinary shares
TipRanks · 10h ago
Alterity Discloses Regal Funds’ Derivative Positions Under Takeovers Panel Guidance
TipRanks · 4d ago
Canaccord Genuity Sticks to Their Buy Rating for Alterity Therapeutics (PRNAF)
TipRanks · 08/13 23:35
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Barchart · 08/12 06:05
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
TipRanks · 08/11 13:11
Alterity Therapeutics initiated with a Buy at Craig-Hallum
TipRanks · 08/11 11:25
Alterity Therapeutics Expands Equity Base With New ASX Share Quotation
TipRanks · 08/10 08:17
Alterity Therapeutics to Highlight MSA Program at Canaccord Growth Conference
TipRanks · 08/06 00:19
More
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd stock information, including OTCPK: PRNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRNAF stock methods without spending real money on the virtual paper trading platform.